Tech Company Financing Transactions

Cerevance Funding Round

Cerevance, based in Boston, secured $47 million from Agent Capital, Bioluminescence Ventures and Double Point Ventures.

Transaction Overview

Company Name
Cerevance
Announced On
4/25/2024
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series B
Investors

Agent Capital (Lead Investor) (Campbell Murray)

Bioluminescence Ventures (Lead Investor) (Kouki Harasaki)

Double Point Ventures (Lead Investor)

Gates Frontier Fund

GV (David Schenkein)

Lightstone Ventures

Proceeds Purpose
Proceeds from this financing will support the upcoming Phase 3 clinical trial for CVN424, a first-in-class non-dopamine therapy for patients with Parkinson's disease, as well as the advancement of a pipeline of novel treatments for other CNS disorders, including Alzheimer's disease, Amyotrophic lateral sclerosis, and frontotemporal dementia.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 1410
Boston, MA 02210
USA
Phone
Undisclosed
Website
www.cerevance.com
Email Address
[email protected]
Overview
Cerevance is a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders.
Profile
Cerevance LinkedIn Company Profile
Social Media
Cerevance Company Twitter Account
Company News
Cerevance News
Facebook
Cerevance on Facebook
YouTube
Cerevance on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Brad Margus
  Brad Margus LinkedIn Profile  Brad Margus Twitter Account  Brad Margus News  Brad Margus on Facebook
Chief Financial Officer
Robert Middlebrook
  Robert Middlebrook LinkedIn Profile  Robert Middlebrook Twitter Account  Robert Middlebrook News  Robert Middlebrook on Facebook
Chief Scientific Officer
Mark Carlton
  Mark Carlton LinkedIn Profile  Mark Carlton Twitter Account  Mark Carlton News  Mark Carlton on Facebook
Chief Scientific Officer
Nathaniel Heintz
  Nathaniel Heintz LinkedIn Profile  Nathaniel Heintz Twitter Account  Nathaniel Heintz News  Nathaniel Heintz on Facebook
Vice President
Roland Bürli
  Roland Bürli LinkedIn Profile  Roland Bürli Twitter Account  Roland Bürli News  Roland Bürli on Facebook
Vice President
Lee Dawson
  Lee Dawson LinkedIn Profile  Lee Dawson Twitter Account  Lee Dawson News  Lee Dawson on Facebook
Vice President
David Margolin
  David Margolin LinkedIn Profile  David Margolin Twitter Account  David Margolin News  David Margolin on Facebook
VP - Bus. Development
Ted Hibben
  Ted Hibben LinkedIn Profile  Ted Hibben Twitter Account  Ted Hibben News  Ted Hibben on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/25/2024: AtaCor Medical venture capital transaction
Next: 4/25/2024: roclub venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.